单位：[1]Department of Hematology, Beijing Friendship Hospital, Capital Medical University, 95 Yong An Road, Xicheng District, Beijing 100050, China临床科室血液科血液科首都医科大学附属北京友谊医院
National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81871633]; Beijing Natural Science FoundationBeijing Natural Science Foundation [7181003]; Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding [ZYLX201702]; Beijing Municipal Administration of Hospitals' Ascent Plan [DFL20180101]
第一作者单位：[1]Department of Hematology, Beijing Friendship Hospital, Capital Medical University, 95 Yong An Road, Xicheng District, Beijing 100050, China
通讯作者：
推荐引用方式(GB/T 7714)：
Jin Zhili,Wang Yini,Wang Jingshi,et al.Long-term survival benefit of ruxolitinib in a patient with relapsed refractory chronic active Epstein-Barr virus[J].ANNALS of HEMATOLOGY.2019,98(8):2003-2004.doi:10.1007/s00277-019-03647-5.
APA：
Jin, Zhili,Wang, Yini,Wang, Jingshi,Zhang, Jia,Wu, Lin&Wang, Zhao.(2019).Long-term survival benefit of ruxolitinib in a patient with relapsed refractory chronic active Epstein-Barr virus.ANNALS of HEMATOLOGY,98,(8)
MLA：
Jin, Zhili,et al."Long-term survival benefit of ruxolitinib in a patient with relapsed refractory chronic active Epstein-Barr virus".ANNALS of HEMATOLOGY 98..8(2019):2003-2004
